S&P 500   2,997.95 (+0.28%)
DOW   27,025.88 (+0.09%)
QQQ   193.41 (+0.19%)
AAPL   234.33 (-0.02%)
FB   189.67 (+0.06%)
MSFT   139.47 (-0.67%)
GOOGL   1,253.85 (+0.87%)
CGC   20.31 (+2.94%)
NVDA   192.60 (-0.83%)
MU   45.44 (+0.62%)
GE   9.07 (+1.80%)
TSLA   262.42 (+1.03%)
AMD   31.02 (+0.68%)
T   37.78 (-0.03%)
F   9.10 (+0.33%)
ACB   3.80 (+5.27%)
PRI   123.96 (+0.07%)
NFLX   293.35 (+2.47%)
BAC   30.07 (-0.33%)
DIS   132.86 (+1.53%)
S&P 500   2,997.95 (+0.28%)
DOW   27,025.88 (+0.09%)
QQQ   193.41 (+0.19%)
AAPL   234.33 (-0.02%)
FB   189.67 (+0.06%)
MSFT   139.47 (-0.67%)
GOOGL   1,253.85 (+0.87%)
CGC   20.31 (+2.94%)
NVDA   192.60 (-0.83%)
MU   45.44 (+0.62%)
GE   9.07 (+1.80%)
TSLA   262.42 (+1.03%)
AMD   31.02 (+0.68%)
T   37.78 (-0.03%)
F   9.10 (+0.33%)
ACB   3.80 (+5.27%)
PRI   123.96 (+0.07%)
NFLX   293.35 (+2.47%)
BAC   30.07 (-0.33%)
DIS   132.86 (+1.53%)
Log in

Basilea Pharmaceutica Stock Price, News & Analysis (OTCMKTS:BPMUF)

$42.28
0.00 (0.00 %)
(As of 10/17/2019 04:00 PM ET)
Today's Range
$42.28
Now: $42.28
$42.28
50-Day Range
$42.28
MA: $43.73
$44.81
52-Week Range
$36.59
Now: $42.28
$54.00
VolumeN/A
Average Volume3 shs
Market Capitalization$501.86 million
P/E RatioN/A
Dividend YieldN/A
Beta1.08
Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers isavuconazole, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, the European Union, and internationally under the Cresemba brand. The company also provides ceftobiprole, an intravenous antibiotic for the treatment of adult patients with community and hospital-acquired pneumonia, excluding ventilator-associated pneumonia under the Zevtera name in European and various non-European countries. In addition, it engages in developing Derazantinib, an orally administered small molecule inhibitor, which is in a clinical study for the treatment intrahepatic cholangiocarcinoma, a form of biliary tract cancer; BAL101553, a tumor checkpoint controller drug for tumor types unresponsive to standard therapeutics; and BAL3833, an orally available small-molecule drug candidate for use as a panRAF/SRC kinase inhibitor targeting cell signaling pathways. The company was founded in 2000 and is headquartered in Basel, Switzerland.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:BPMUF
CUSIPN/A
CIKN/A
Phone41-61-606-1111

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$103.15 million
Book Value($3.55) per share

Profitability

Miscellaneous

Employees227
Market Cap$501.86 million
Next Earnings DateN/A
OptionableNot Optionable

Receive BPMUF News and Ratings via Email

Sign-up to receive the latest news and ratings for BPMUF and its competitors with MarketBeat's FREE daily newsletter.


Basilea Pharmaceutica (OTCMKTS:BPMUF) Frequently Asked Questions

What is Basilea Pharmaceutica's stock symbol?

Basilea Pharmaceutica trades on the OTCMKTS under the ticker symbol "BPMUF."

What is the consensus analysts' recommendation for Basilea Pharmaceutica?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Basilea Pharmaceutica in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Basilea Pharmaceutica.

Has Basilea Pharmaceutica been receiving favorable news coverage?

Press coverage about BPMUF stock has been trending somewhat positive this week, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Basilea Pharmaceutica earned a news sentiment score of 1.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Basilea Pharmaceutica.

Who are some of Basilea Pharmaceutica's key competitors?

What other stocks do shareholders of Basilea Pharmaceutica own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Basilea Pharmaceutica investors own include BIOLINERX LTD/S (BLRX), ImmunoGen (IMGN), Myriad Genetics (MYGN), AC Immune (ACIU), Affimed (AFMD), Applied Genetic Technologies (AGTC), BIOFRONTERA AG/ADR (BFRA), Bellicum Pharmaceuticals (BLCM), Bellerophon Therapeutics (BLPH) and bluebird bio (BLUE).

Who are Basilea Pharmaceutica's key executives?

Basilea Pharmaceutica's management team includes the folowing people:
  • Mr. David Veitch, Chief Exec. Officer (Age 54)
  • Mr. Adesh Kaul, Chief Financial Officer (Age 45)
  • Dr. Laurenz Kellenberger, Chief Scientific Officer (Age 52)
  • Dr. Marc Engelhardt, Chief Medical Officer (Age 55)
  • Dr. Gerrit Hauck, Chief Technology Officer (Age 55)

How do I buy shares of Basilea Pharmaceutica?

Shares of BPMUF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Basilea Pharmaceutica's stock price today?

One share of BPMUF stock can currently be purchased for approximately $42.28.

How big of a company is Basilea Pharmaceutica?

Basilea Pharmaceutica has a market capitalization of $501.86 million and generates $103.15 million in revenue each year. Basilea Pharmaceutica employs 227 workers across the globe.View Additional Information About Basilea Pharmaceutica.

What is Basilea Pharmaceutica's official website?

The official website for Basilea Pharmaceutica is http://www.basilea.com/.

How can I contact Basilea Pharmaceutica?

Basilea Pharmaceutica's mailing address is Grenzacherstrasse 487, Basel V8, 4058. The company can be reached via phone at 41-61-606-1111 or via email at [email protected]


MarketBeat Community Rating for Basilea Pharmaceutica (OTCMKTS BPMUF)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  20 (Thanks for Voting!)
Underperform Votes:  22 (Thanks for Voting!)
Total Votes:  42
MarketBeat's community ratings are surveys of what our community members think about Basilea Pharmaceutica and other stocks. Vote "Outperform" if you believe BPMUF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BPMUF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel